Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

platform.  This technology enhances delivery of key target proteins like HER2 for cancer to a critical immune recognition site enhancing immune recognition. The Company has also developed compounds designed for important non-HER2 cancer associated protein targets using the Ii-Key technology platform. These include the melanoma-associated gp100 target, as well as cervical and head-and-neck cancers associated with Human Papilloma Virus (HPV). These compounds have shown significant activity in animal models that has been described in peer-reviewed publications.

In addition to cancer protein targets, the Company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.

The distinguishing feature of Antigen Express technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the Company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... 2011 Covance Inc. (NYSE: CVD ) today ... Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
... IRVINE, Calif., Feb. 22, 2011 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and twelve ... Endologix President and Chief Executive Officer, said, "We made tremendous ... quarter of 2010.  Revenue grew by 41% over the corresponding ...
Cached Medicine Technology:Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 3Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 4Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 5Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 6Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 7Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 8Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 9Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 10
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... the student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 ... This is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Aug. 3 Blue Cross and Blue Shield of Georgia ... administration of the H1N1 (swine flu) vaccine when it becomes ... be covered for members whose benefit plans provide coverage for ... coverage of seasonal flu vaccine administration for those whose health ...
... A new class of antibody drugs may provide a powerful ... but specialists need to be alert for the possibility of ... Journal of AAPOS (American Association for Pediatric Ophthalmology ... of Santa Barbara, Calif., discusses issues related to the use ...
... of synthetic biology will, in the medium term, open up ... with engineering principles. This will facilitate the development, not only ... new materials. Early-stage dialogue with the public on the natural ... success and acceptance of this new technology. With a joint ...
... 3 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast: , , ... When: Friday, August 14, 2009 at 12:00 PM ET, ... Live over the Internet -- Simply log on to the web at the, ... Conference call dial-in phone numbers:, Toll-free from the US: ...
... , SILVER SPRING, Md., Aug. 3 Four ... session of ongoing couples therapy can greatly increase chances for ... The largest clinical trial with couples to date, it shows ... feedback technique were 46.2 percent less than that of couples ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) ... E. ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... and his extensive knowledge of PDL,s humanization technology will allow him ... seek to maximize the value of our antibody humanization patents and ...
Cached Medicine News:Health News:BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases 2Health News:Synthetic biology -- opportunities and risks 2Health News:Synthetic biology -- opportunities and risks 3Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
HME only...
Medicine Products: